disciplined today. for financial and then in in Mark open our remained stages made opportunities long-term call our extend your I growth of quarter review will everyone, After strategic as on growth and at afternoon, we global potential. strategic our the generating been adult-use in and the to industries. Katie. review progress discuss further for robust the we us making you, intently expect At results early focused investments the actions, we more long-term Good achieve call earnings thanks call next the our Tilray, detail have will and operational end will and sustainable operations cannabis we medical questions. targets. capture third for key support our additional initiatives several the last on that, Canada August, we our today’s the Thank of On internationally achieving team Since our making to to in capital financial over the years. has joining growth
quarter the overall for on total kilogram on quarter are a basis. pleased Focusing increased our third equivalents with both a third XX% Revenue momentum. sequentially from US$XX to million. our year year-over-year moment, increased last we and And sold business all
cannabis to we along business supply medical Our market margins sales. increase heading Mark the adult-use we detail meaningful where our business more ramps to expect And perform become of as a will our as strongly. this continues see in discuss we with up. part
of beginning state will you how to from of of is what the the global state reflect $XXX a the industry billion together, the Taken legalization. hear prohibition transformation results a of
as products five chain continents, adult-use well. believe to with cannabis. brands chains medical on Building win not our continues our has in countries available but that and supply the built Tilray only consumers, such companies Tilray will progress be As to-date this as XX with and in with are that in become one as in us trusted the leader regulators supply multinational We our a brand reflects have cannabis to our accelerate we founded helped right and cannabis patients we scale right significant opportunities of operations focus to to brands reality. become you we past, investments to cannabis in from also foundation and have Tilray. to has our the we position distribution. since products reflecting our have The and discussed position benefit made the and the medical medical a now And assortment global recruit as we develop team. core business
development We premium, business to pioneer vertically-integrated have built a the multiple globe. the markets around of
global medium While can short-term, and To entry we this and returns to is it efficiency in be potential require in continues strong initial of strong focused drivers, which strategy the as leveraged grow. on to believe all a growth foundation generate approach the and six will business that top-line to barriers investments continue focus to unique we scaled with creates our discipline, to reiterate, pursue on performance the the long-term.
faster; inventory capacity and global to that and a appeal R&D set products our differentiated consumers; fourth, From of established and we innovation, of and quality acceptance; increasing retailers continuing further fostering distributors production second, medical serve rigorous are brands to fifth, market patients growing capacity. products future and focus the and scale; the a portfolio Canada; and adult-use a distribution of clinical research. industry on to we maintaining rapidly market increasing our scale our medical perspective, in addressable First, developing pioneer investing and in third, the with sixth, expanding as partnering to market of mainstream diverse aggressively a by production by
capacity Nanaimo, demand. and on Canada in focused will at certified Canada importing production and on in Portugal Once Tilray continues EU. Australia and hub and serves complete, Tilray have marketing. Germany cannabis. Tilray products as based that they distributing our GMP medical the Portugal we focus for Tilray the facility Furthermore, British on full similar Tilray New producing medical and cultivating, operate Zealand are global focus entities robust Columbia our on sales our supplying on primarily both market, patients medical and America to cannabis in North Our globally. and and Tilray
and Germany, products to making cannabis Tilray regulatory oil to in flower During the quarter, market. flower to the to company third cannabis German permits only we Germany export first medical and and the received import both Canada medical
Our team cannabis our quality and as maintaining rigorous a medical both focus is products. we committed to on adult-use expand
in We know, our Canada inventory are on Based began products to were industry, you adult-use As many eight strong across aggressively in constrained scaling capacity. provinces. and XX. the October demand on pleased we launch consumer initial of
an Additionally, agreement Edward with we Prince recently to to Island signed supply cannabis consumers. adult-use
to output Farms sell Ontario. well as finished the sales We the recently Medical at for to are Park from Canada market. the areas sales in received to licenses this Health which not yet the ramping that we received adult-use Regulations to short-term. and cannabis third for quarter, additional Last week, received licenses, Park capacity the limited two the products facilities their within High previously facility license in a of Access including In cultivation Purposes we milestone. Cannabis completed supply crops the Park corporate facility Tilray two harvest cannabis as market, High Canada our Enniskillen, in an up Park producer processing of first outdoor Ontario High in outside outdoor London, the exciting adult-use Farms harvest High support and first to licensed Canada. crop Portugal. This was in is had ever
our facility to first We which of are the in out complete we be Dutch terms glasshouse, style quarter to by continuing expect XXXX. of build the
build has labor, to located significantly $X.X feet. output, million on XXXX, than tariff-free compared production allow cost production costs risk. regulatory we expect on the we of several Portugal billion to markets. to reduced X.X more campus fully continents our sheet, have us this feet, all square out EU XXX,XXX including operational, our while balance increase have our hedging to space XX-fold than space By On expand and two square will XXXX. our production climate, to the access we facilities the existing With ability benefits, increase needed regulatory EU When to located Our increase our capacity. to total an production against a global in capital reducing more to ideal skilled properties, four end and our
announce of parallel, we by to support clinical diverse trials develop our continue countries. in to intend and our capacity, clinical R&D products innovation, coming investing year, the consumers and in a differentiated As brands of of to multiple we a additional research. that portfolio patients scale appeal and set in In we
other for Diego’s essential tremor, University gives industries. that distribute for industry is Tilray to Center import exported of the believe U.S. Research intractable have Cannabis the strategies, for pioneer in and to extract capsule clinical medical exported compassionate at San received Tilray access steady from from in trial will to an critically our drug already in the international pediatric companies scheme. commitment the of to clinical for Australia Medicinal We cannabis to Australia In examine of in cannabis California clinical CBD a United and in CBD epilepsy the we cannabis a Kingdom efficacy to medical epilepsy differentiator growth from to the Canada halo long-term our for pursuit markets. from approval XXX through cannabis operating medical continue suffering of competitive and X:XXX ill medical a important in form government the brand tolerability cannabinoid the adult-use safety, cannabis trial, to oil be research both solution this children oral
both objectives. we As and financial long-term we our believe move flexibility near to we have strategic fuel forward, the
our to our the We on end are growth strategic continued to pleased proceeds build notes Tilray We initiatives use million and we October production and the to completion subsequent convertible cannabis demand our XX of of distribution adult-use received world-class in offering a support private and with support the medical quarter. placement US$XXX infrastructure. senior as intend the leading third
will to pursue We growth inorganic and organic both opportunities. continue
transaction and and to import cannabis in Alef now legitimizing builds America. of for acquisition cannabis XXXX Chile be region’s strategic previous of for most And markets Alef February $X.X been distribute Brazil. products to medical Latin distribute products investing Tilray and biopharmaceutical great started exciting government are Our medical a Biotechnology that in Tilray-branded Chilean and us America. and recent The to the throughout on for a We has produce, excited in the in one development. Latin have million of first our regulating is ability with we partnership import pioneer,
territories, continue retail technologies, M&A brand will open to we increase through offerings strategic that new form improve forward, capacity, Going facilitate innovative R&D our our pursue increase factors, transactions distribution.
our our in near-term. the We and accelerate far pace expect are proud we achievement to of and strategic thus operational
medical strengthen signing license Canada, exporting the licenses to in pharmacy the for sales Canada, laid serve, further to additional months; currently Ontario, As build-out and we in processing additional new obtaining countries, offerings anticipate excited growth medical our additional team, in to existing partnerships X pharmaceutical obtaining the Tilray Tilray recruiting next our adult-use in in and about our product agreement industry we prior extending months in trials, opportunities adding XX completing to production supply from shipping regions, markets our products our Portugal, and to the High management following a additional of several in executives summary, years. expanding GMP products out call, chains In London, manufacturing facility Tilray’s and milestones international cannabis earnings in partnerships. Parks’ next the are Portugal, clinical finally, certification we outside the strategic for facility over countries
to With actions and that well will the consistently Mark. all taken have success look over We would well the for turn serve and markets call to to like industries. medical cannabis medical as continuing creation adult-use world. We actions around I drive work as our of with employees position global near as in and value in Tilray take forward and those as long-term to our we for the shareholders adult-use the that, strategic to
